医院的细胞毒性表面污染:目前的做法、挑战和前景。

IF 1 4区 医学 Q4 ONCOLOGY
Bertrand Favier, Claire Simonin, Sophie Tokatian, Jérôme Guitton, Sophie Darnis, Mathurine Basset, Sylvie Chabaud, Laurence Gilles
{"title":"医院的细胞毒性表面污染:目前的做法、挑战和前景。","authors":"Bertrand Favier, Claire Simonin, Sophie Tokatian, Jérôme Guitton, Sophie Darnis, Mathurine Basset, Sylvie Chabaud, Laurence Gilles","doi":"10.1177/10781552241307905","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Despite significant advances in cancer treatment with targeted therapies and immunotherapies, cytotoxic chemotherapies are still extensively used. Potential cytotoxic contamination in preparing and administrating cytotoxics is still a major source of concern. Besides advanced protections including biological safety cabinets, work surface contamination needs to be continuously controlled to ensure that handling procedures and cleaning were appropriate. Contamination monitoring needs to be standardized.</p><p><strong>Data sources: </strong>The study searched Pubmed/Medline and Embase with\"hazardous drug\", \"cytotoxic drug\", \"surface contamination\", \"environmental contamination\", \"wipe sample\", \"pharmacy\", \"care unit\", and selected studies reporting contamination results in work environment for pharmacy technicians and nurses, from 1 January 2017 to 31 December 2022.</p><p><strong>Data summary: </strong>The 29 studies totalized 16,196 samples and 189,571 assays. Contamination results showed 39.8% sample positivity, and 8.2% assay positivity. Multicentric studies gathering at least 500 samples or up to 800 samples would limit heterogeneity in sample positivity. In addition, monitoring of an appropriate tracer selection including at least the 7 tracers with the highest contamination frequencies (cyclophosphamide, gemcitabine, fluorouracile, ifosfamide, platinum derivatives, paclitaxel and methotrexate) would facilitate contamination comparisons amongst studies and local results. Most recent studies reported thresholds for cyclophosphamide close to 0.1 ng/cm² at the 90<sup>th</sup> percentile.</p><p><strong>Conclusions: </strong>The overall risk of exposure for healthcare professionals is a major concern. Sample size in multicentric studies would require at least 500 samples; quantification of all tracers with the highest contamination frequencies need to be quantified. This approach would provide a basis to develop guidelines to appropriately monitor contamination in pharmacies and patient care area managers.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552241307905"},"PeriodicalIF":1.0000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cytotoxic surface contamination in hospitals: Current practices, challenges and perspectives.\",\"authors\":\"Bertrand Favier, Claire Simonin, Sophie Tokatian, Jérôme Guitton, Sophie Darnis, Mathurine Basset, Sylvie Chabaud, Laurence Gilles\",\"doi\":\"10.1177/10781552241307905\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Despite significant advances in cancer treatment with targeted therapies and immunotherapies, cytotoxic chemotherapies are still extensively used. Potential cytotoxic contamination in preparing and administrating cytotoxics is still a major source of concern. Besides advanced protections including biological safety cabinets, work surface contamination needs to be continuously controlled to ensure that handling procedures and cleaning were appropriate. Contamination monitoring needs to be standardized.</p><p><strong>Data sources: </strong>The study searched Pubmed/Medline and Embase with\\\"hazardous drug\\\", \\\"cytotoxic drug\\\", \\\"surface contamination\\\", \\\"environmental contamination\\\", \\\"wipe sample\\\", \\\"pharmacy\\\", \\\"care unit\\\", and selected studies reporting contamination results in work environment for pharmacy technicians and nurses, from 1 January 2017 to 31 December 2022.</p><p><strong>Data summary: </strong>The 29 studies totalized 16,196 samples and 189,571 assays. Contamination results showed 39.8% sample positivity, and 8.2% assay positivity. Multicentric studies gathering at least 500 samples or up to 800 samples would limit heterogeneity in sample positivity. In addition, monitoring of an appropriate tracer selection including at least the 7 tracers with the highest contamination frequencies (cyclophosphamide, gemcitabine, fluorouracile, ifosfamide, platinum derivatives, paclitaxel and methotrexate) would facilitate contamination comparisons amongst studies and local results. Most recent studies reported thresholds for cyclophosphamide close to 0.1 ng/cm² at the 90<sup>th</sup> percentile.</p><p><strong>Conclusions: </strong>The overall risk of exposure for healthcare professionals is a major concern. Sample size in multicentric studies would require at least 500 samples; quantification of all tracers with the highest contamination frequencies need to be quantified. This approach would provide a basis to develop guidelines to appropriately monitor contamination in pharmacies and patient care area managers.</p>\",\"PeriodicalId\":16637,\"journal\":{\"name\":\"Journal of Oncology Pharmacy Practice\",\"volume\":\" \",\"pages\":\"10781552241307905\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Oncology Pharmacy Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10781552241307905\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552241307905","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:尽管靶向治疗和免疫治疗在癌症治疗方面取得了重大进展,但细胞毒性化疗仍被广泛使用。在制备和施用细胞毒素过程中潜在的细胞毒性污染仍然是一个主要的关注来源。除了先进的保护措施,包括生物安全柜,工作表面污染需要持续控制,以确保处理程序和清洁是适当的。污染监测需要标准化。数据来源:从2017年1月1日至2022年12月31日,该研究用“危险药物”、“细胞毒性药物”、“表面污染”、“环境污染”、“擦拭样本”、“药房”、“护理单位”和报告药房技术人员和护士工作环境污染结果的选定研究搜索了Pubmed/Medline和Embase。数据总结:29项研究共16,196个样本和189,571个分析。污染结果样品阳性39.8%,检测阳性8.2%。收集至少500个样本或多达800个样本的多中心研究将限制样本阳性的异质性。此外,监测适当的示踪剂选择,包括至少7种污染频率最高的示踪剂(环磷酰胺、吉西他滨、氟尿嘧啶、异环磷酰胺、铂衍生物、紫杉醇和甲氨蝶呤),将有助于在研究和当地结果之间进行污染比较。最近的大多数研究报告环磷酰胺的阈值在第90百分位数接近0.1纳克/平方厘米。结论:卫生保健专业人员的总体暴露风险是一个主要问题。多中心研究的样本量至少需要500个样本;所有污染频率最高的示踪剂都需要定量。这种方法将为制定指导方针提供基础,以适当监测药房和病人护理区域管理人员的污染情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cytotoxic surface contamination in hospitals: Current practices, challenges and perspectives.

Objective: Despite significant advances in cancer treatment with targeted therapies and immunotherapies, cytotoxic chemotherapies are still extensively used. Potential cytotoxic contamination in preparing and administrating cytotoxics is still a major source of concern. Besides advanced protections including biological safety cabinets, work surface contamination needs to be continuously controlled to ensure that handling procedures and cleaning were appropriate. Contamination monitoring needs to be standardized.

Data sources: The study searched Pubmed/Medline and Embase with"hazardous drug", "cytotoxic drug", "surface contamination", "environmental contamination", "wipe sample", "pharmacy", "care unit", and selected studies reporting contamination results in work environment for pharmacy technicians and nurses, from 1 January 2017 to 31 December 2022.

Data summary: The 29 studies totalized 16,196 samples and 189,571 assays. Contamination results showed 39.8% sample positivity, and 8.2% assay positivity. Multicentric studies gathering at least 500 samples or up to 800 samples would limit heterogeneity in sample positivity. In addition, monitoring of an appropriate tracer selection including at least the 7 tracers with the highest contamination frequencies (cyclophosphamide, gemcitabine, fluorouracile, ifosfamide, platinum derivatives, paclitaxel and methotrexate) would facilitate contamination comparisons amongst studies and local results. Most recent studies reported thresholds for cyclophosphamide close to 0.1 ng/cm² at the 90th percentile.

Conclusions: The overall risk of exposure for healthcare professionals is a major concern. Sample size in multicentric studies would require at least 500 samples; quantification of all tracers with the highest contamination frequencies need to be quantified. This approach would provide a basis to develop guidelines to appropriately monitor contamination in pharmacies and patient care area managers.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.70
自引率
7.70%
发文量
276
期刊介绍: Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信